Synthetic substance. The dose is in larger parts not metabolised. No clinically significant CYP-interactions observed.

Synthetic and selective inhibitor of activated factor X. Administered subcutaneously, 2.5 mg/d, for prevention agaist thromoembolic episodes in patients undergoing orthopedic surgery. Excreted in unchanged form to 64-77%. Has been shown not to inhibit the metabolism of CYP metabolized drugs.